8-KItem 5.02 · Officer/Director Change

Charles River ($CRL): Board announces CEO/Chair transition — James C.

Filed with the SEC on · Summarized by InvestorsBot

Charles River ($CRL): Board announces CEO/Chair transition — James C. Foster to step down as CEO & Chair; COO Birgit Girshick named CEO effective May 5, 2026. Foster to remain a non‑exec director; Lead Independent Director Martin Mackay to become Chair. 🧬 #leadership #biotech

$CRL: Birgit Girshick compensation highlights — base salary ↑ to $1.2M (eff. Feb 1, 2026); target cash incentive = 100% of salary (eff. May 1, 2026); initial equity grant target FMV $9.0M (80% PSUs / 20% RSUs, expected May 2026). 💰 #compensation #governance

$CRL: Change‑in‑control/severance for Girshick (to be in amended CIC): if terminated pre‑1st anniversary of a change in control without cause or for “good reason,” she’d get 3×(salary + target bonus) lump sum, 3 years benefits continuation + outplacement. 🔁 #governance #M&A

$CRL: In recognition of 2026 service, James Foster to receive RSUs with underlying FMV $3.0M (grant expected Mar 2, 2026) with a 2‑year cliff vest; after the 2026 annual meeting he’s expected to receive standard non‑exec director compensation. 🪙 #executivepay #governance

Read the original filing on SEC EDGAR

Get summaries like this in your inbox every morning

Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.

Subscribe free

More from CHARLES RIVER LABORATORIES INTERNATIONAL, INC.